New melanoma treatment triggers cell death
Australian scientists led by the Centenary Institute have reported a new strategy to battle melanoma, the most common form of cancer affecting young Australians (aged 15–39) and the most dangerous form of skin cancer, responsible for approximately 1700 deaths in Australia each year.
Using drugs to inhibit two separate proteins, the researchers found that they could effectively kill melanoma cells by inducing apoptosis (the process of cellular self-destruction that takes place when a cell is no longer needed). Described in the International Journal of Cancer, the treatment strategy has the potential to benefit a subgroup of melanoma patients who do not respond to targeted therapies or immunotherapy.
“Provoking apoptosis has proven extremely difficult due to the high expression of anti-apoptotic or ‘protector’ proteins found in melanoma cancer cells,” said Dr Hsin-Yi Tseng, Research Officer at the Centenary Institute and lead author of the study.
“These protector proteins help the melanoma cell to survive, thrive and, in some cases, to aid resistance against advanced medical drug treatments.”
The study saw the researchers inhibit the protein MCL1, together with proteins from the bromodomain and extra-terminal (BET) family. Both are known to have key roles in protecting and supporting melanoma cancer cells inside the body.
“Our research showed that combining BET and MCL1 inhibitors is highly effective at killing melanoma,” Dr Tseng said. “The protective abilities of the BET and MCL1 proteins are decreased by the drug inhibitors and also induce the cancer cells to self-destruct.”
Senior co-author Dr Jessamy Tiffen, also from the Centenary Institute, said the team’s research is highly significant and offers up a potential new treatment strategy for melanoma patients.
“Up to one half of melanoma patients do not respond to immunotherapy and a majority of patients tend to develop acquired resistance to targeted therapies,” Dr Tiffen said. “Our research examined a large number of human melanoma cell lines as well as use of mouse models. We saw extensive melanoma reduction in both cases, which bodes well for the translation of this research into the next stage of development.”
Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.
Long COVID abnormalities appear to resolve over time
Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...
RNA-targeted therapy shows promise for childhood dementia
Scientists have shown that a new RNA-targeted therapy can halt the progression of a specific type...
Parkinson's alters emotion-related bodily sensations
People with Parkinson's disease were found to have significant differences in all bodily...
